2 weeks Ago By Defense World Staff
Alkermes ( NASDAQ:ALKS – Get Free Report ) had its price objective raised by equities researchers at Mizuho from $35.00 to $40.00 in a report released on Wednesday, Benzinga reports.
The firm currently has an “outperform” rating on the stock. Mizuho’s price target points to a potential upside of 41.09% from the company’s previous close.
Several other brokerages have also recently weighed in on ALKS. Robert W. Baird lifted their price objective on Alkermes from $37.
00 to $38.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. The Goldman Sachs Group reduced their price objective on Alkermes from $32.
00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. HC Wainwright restated a “neutral” rating and set a $37.
00 price objective on shares of Alkermes in a research report on Friday, October 25th. Cantor Fitzgerald reduced their price target on Alkermes from $48.00 to $43.
00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. Finally, JPMorgan Chase & Co. dropped their price objective on Alkermes from $32.
00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the stock.
Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.42.
View Our Latest Analysis on Alkermes Alkermes Stock Performance Insiders Place Their Bets In related news, EVP Craig C. Hopkinson sold 58,996 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.
08, for a total transaction of $1,774,599.68. Following the transaction, the executive vice president now owns 83,300 shares in the company, valued at $2,505,664.
The trade was a 41.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link .
Corporate insiders own 4.89% of the company’s stock. Institutional Trading of Alkermes A number of hedge funds have recently made changes to their positions in the stock.
Price T Rowe Associates Inc. MD lifted its position in Alkermes by 421.8% in the 1st quarter.
Price T Rowe Associates Inc. MD now owns 8,326,256 shares of the company’s stock valued at $225,393,000 after acquiring an additional 6,730,671 shares in the last quarter. Pacer Advisors Inc.
increased its stake in Alkermes by 31.8% in the 2nd quarter. Pacer Advisors Inc.
now owns 5,640,642 shares of the company’s stock worth $135,939,000 after buying an additional 1,362,079 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Alkermes by 14.8% in the 2nd quarter.
Dimensional Fund Advisors LP now owns 2,884,012 shares of the company’s stock worth $69,507,000 after buying an additional 371,039 shares in the last quarter. Armistice Capital LLC increased its stake in Alkermes by 301.5% in the 2nd quarter.
Armistice Capital LLC now owns 2,699,179 shares of the company’s stock worth $65,050,000 after buying an additional 2,026,961 shares in the last quarter. Finally, American Century Companies Inc. boosted its holdings in shares of Alkermes by 87.
1% during the 2nd quarter. American Century Companies Inc. now owns 2,203,456 shares of the company’s stock valued at $53,103,000 after purchasing an additional 1,025,905 shares during the last quarter.
95.21% of the stock is owned by institutional investors. Alkermes Company Profile ( Get Free Report ) Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Featured Articles Five stocks we like better than Alkermes Insider Selling Explained: Can it Inform Your Investing Choices? 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick Utilities Stocks Explained – How and Why to Invest in Utilities Mouse Rising: The Iger Investment Pays Off for Disney Investors How to invest in marijuana stocks in 7 steps Can CAVA Stock Be the Next Chipotle? Earnings Can Help Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter .
.
